Kelun-Biotech trial shows 31% lower death risk versus chemotherapy
Final overall survival results from Phase III OptiTROP-Lung04 showed sac-TMT monotherapy cut the risk of death by 31% versus a platinum doublet in EGFR-mutant NSCLC after EGFR-TKI. No new safety signals were reported after 32.3 months’ median follow-up.